For all of last year, Illumina’s net loss grew 5% from $1.161 billion to $1.223 billion, on revenue that fell 3% from $4.505 ...

Star portfolio manager Cathie Wood’s Ark Investment Management filed its 13F holdings report for the fourth quarter on Feb. 4 ...

Illumina is part of the Health Care sector, which has an average P/E ratio of 26.07 and an average P/B of 3.53 The company has a free cash flow of $343.12 Million, which refers to the total sum of all ...

Illumina shares tumbled 8% Friday on investor concerns about the future of the gene-sequencing equipment maker’s business in ...

After China placed Illumina on a government watchlist this week, in response to new tariffs imposed by the Trump ...

ILMN reported fourth-quarter 2024 adjusted earnings per share (EPS) of 86 cents, which missed the Zacks Consensus Estimate of 92 cents by 6.5%. The bottom line was significantly above the year-ago ...

Q4 2024 Earnings Call Transcript February 6, 2025 Illumina, Inc. misses on earnings expectations. Reported EPS is $0.91 EPS, ...

TD Cowen downgraded Illumina (ILMN) to Hold from Buy with a price target of $140, down from $177. Accelerating high throughput next-generation ...

Citi analyst Patrick Donnelly lowered the firm’s price target on Illumina (ILMN) to $130 from $165 and keeps a Neutral rating on the shares ...

Illumina Inc (ILMN) reports steady revenue growth and strategic advancements, while addressing competitive pressures and geopolitical risks.

CEO Jacob Thaysen highlighted the transformative progress Illumina made in 2024, emphasizing its strategic roadmap targeting high single-digit revenue growth by 2027. He noted significant advancements ...